What is Ustekinumab Biosimilar research grade? Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohns Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.
